Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The Actual Benefit of XEROQUEL LP in the treatment of schizophrenia is substantial. |
Clinical Added Value
| no clinical added value |
XEROQUEL LP does not provide an Improvement in Actual Benefit (IAB level V) compared with other treatments available in this indication. |
eNq1mFFv2jAQx9/5FFHeSUhLoZ0C1cbaDanVGC3atJfKJEcxc+30bAPdp59D6EYnR10Nfozt/O/sO//u5PR8/cCCJaCkgvfCJGqFAfBM5JTf98LJ7WXzNDzvN9IFWZKdZd2oFSVHYZAxImUvLGejKRAuo+/XVx/B/A8Y9htBKqYLyNSLdVpRFn0mcn5NinJNkC4FzYMHUHOR98JCq81okEqFxov+SuBPWZAM0ng7sju7uGvvjqdxKfYfqloCXhF+bxUF7qSZaUTgakAU3At8qvH32EmbyjFIoTGDEVHzEYolzSG3mpgRJsHJyGyV3wAuGajSiFU8XmQP0kmcLMh6DI9Du9PvzexArVWz1Uy6nSRpdY/bZ+1O18kU7hyVPQpmE3F2lxy1k85ZNwYerwHFowbmGJyRQEWYp7BQOXiZWZ7sIDy+Gv6cyoKRp2ghC9ejIkjMNKC5//42Uu7gFg2RmDmzf/S5Zix+o9eTLS88eVziaCA0VzXYuBy7HsRAcAXr+oi6kU6tt7lIQR5O9pfgdsqP9JTRzJVphjoapJqMh/VIOygNPhAJE/SHg2+U52IlD4+Z3bB68r7YkNIqWmCe3B2dnXaSkxPnW/TD5FBNjbnQKAqIDYCo3IcrQz4T+xLFpKVd6jkpD5ePm1ZHZIRBTbPTdKSLScTn3sxbqvu7RtWEVfTTxa1rfnzVgE83m0+rNM17fyLrhl4fPDfZWOv423O7uuJe2mCNdnTMlSrkuzherVbRnMimJOaUohkenu079dRfF+6laFdNTMVHT65Pq8L3thC5XrXXyvq+rer2/21LbLWhUMMesaio7I2dw4vD4/hvn+rN7dELfPgzs+kpiaKC+2p19NSquF8BMHHll2gA8WU2ozWvIrV5mcbVi0y/kcbla0y/8RshDebW
7n6cAGqmGKFSY4Qr
Listen
